16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG

Size: px
Start display at page:

Download "16 TH -17 TH INNOVATIONS IN ONCOLOGY NOVEMBER HEIDELBERG"

Transcription

1 16 TH -17 TH 2015 NOVEMBER INNOVATIONS IN ONCOLOGY HEIDELBERG

2 INNOVATIONS IN ONCOLOGY HEIDELBERG, NOVEMBER 16 TH - 17 TH 2015 German Cancer Research Center (DKFZ) Heidelberg - Germany Hosted by the National Center for Tumor Diseases (NCT) Heidelberg, the German Cancer Research Center (DKFZ), the Felix Burda Foundation and the German Network Against Colorectal Cancer, our 2015 Innovations in Oncology Workshop will bring together scientists and physicians from academics to industry to discuss the latest findings in cancer science and medicine. The workshop is designed to foster interdisciplinary communication and collaboration through an exciting range of sessions and panel discussions on Big Data in Genomic Analysis, Familial Risk of Cancer, Personalized Diagnostics for Targeted Therapies of Cancer and Innovative Therapeutic Approaches of Cancer Immunotherapy. We hope that you will join us at our Innovation Workshop on November, 16 th -17 th 2015 in the beautiful city of Heidelberg and strengthen our links in cancer research and medicine. The Organizing Committee Dr. Christa Maar CEO Felix Burda Foundation President of German Network Against Colorectal Cancer Dr. Georg Ralle General Secretary German Network Against Colorectal Cancer Prof. Dr. Christof von Kalle Director, Translational Oncology National Center for Tumor Diseases Prof. Dr. Dirk Jäger Director, Medical Oncology National Center for Tumor Dieseases

3 SATELLITE SYMPOSIUM* NOVEMBER 16 TH :30 12:00 Welcome Lunch 12:00-14:00 Session: Big Data in Genomic Analysis Challenges & Opportunities Chair: Gerd Maass / Christof von Kalle 12:00 12:20 Comprehensive genomic profiling in oncology clinical care and clinical trials Roman Yelensky, Foundation Medicine Inc., Cambridge 12:30 12:50 Real-time processing of genomic and clinical data Werner Eberhardt, SAP Deutschland SE & Co. KG, Walldorf 13:00 13:20 Engineering the medical revolution big data in clinical decision making Stephan Brock, Molecular Health GmbH, Heidelberg 13:30 13:50 Bioinformatics concepts for the molecular tumor board Benedikt Brors, DKFZ and National Center for Tumor Diseases (NCT), Heidelberg 14:00-14:30 Panel Discussion: Moderation: Gerd Maass Stephan Brock, Molecular Health GmbH, Heidelberg Benedikt Brors, DKFZ and National Center for Tumor Diseases (NCT), Heidelberg Werner Eberhardt, SAP Deutschland SE & Co. KG, Walldorf, Heidelberg Christof von Kalle, National Center for Tumor Diseases (NCT), Heidelberg Roman Yelensky, Foundation Medicine Inc., Cambridge 14:30 15:00 Coffee Break / Get Together *WITH FRIENDLY SUPPORT OF: (PROMOTION AND PRESENTATION) (3.000 ) (5.000 ) ( )

4 NOVEMBER 16 TH :00-15:15 Welcome Speech Christa Maar, German Network Against Colorectal Cancer, Munich Christof von Kalle, National Center for Tumor Diseases (NCT), Heidelberg 15:15-18:15 Session I: Familial Risk of Cancer Chairs: Rita Schmutzler / Christa Maar 15:15-15:35 How to predict breast cancer risk Douglas Easton, University of Cambridge, Cambridge 15:45 16:05 Stratification of breast cancer into 10 genomic driver-based subtypes and its implications Carlos Caldas, University of Cambridge, Cambridge 16:15 16:35 Challenges for the implementation of risk-stratified prevention Kerstin Rhiem, University Hospital Cologne, Cologne 16:45 17:15 Coffee Break 17:15 17:35 Hereditary colorectal cancer Jewel Samadder, Huntsman Cancer Institute, Salt Lake City 17:45 18:05 Title (TBD) Polly A. Newcomb, Fred Hutchinson Cancer Research Center, Seattle

5 NOVEMBER 16 TH :15-19:00 Panel Discussion I: Familial Risk of Cancer Moderation: Christina Berndt / Jörg Rüdiger Siewert Hermann Brenner, German Cancer Research Center (DKFZ), Heidelberg Carlos Caldas, University of Cambridge, Cambridge Douglas Easton, University of Cambridge, Cambridge Christa Maar, German Network Against Colorectal Cancer, Munich Polly A. Newcomb, Fred Hutchinson Cancer Research Center, Seattle Kerstin Rhiem, University Hospital Cologne, Cologne Jewel Samadder, Huntsman Cancer Institute, Utah Rita Schmutzler, University Hospital Cologne, Cologne Barbara Zimmer, Competence Centre Oncology (KCO), Düsseldorf 19:00 20:00 Get Together at DKFZ 20:00 Speakers Dinner

6 NOVEMBER 17 TH :00-11:30 Session II: Personalized Diagnostics for Targeted Therapies of Cancer Chairs: Christof von Kalle / Tim Hubbard 08:00 08:20 The UK 100,000 genomes project: towards personalised health in the NHS (TBC) Tim Hubbard, King s College, London 08:30 08:50 Blood biopsy as a window into tumor heterogeneity Jens G. Lohr, Dana-Farber Cancer Institute, Boston 09:00 09:20 Clinical implementation of cross-entity cancer genome sequencing Stefan Fröhling, National Center for Tumor Diseases (NCT), Heidelberg 09:30 09:50 Precision Medicine: the example of chronic lymphocytic leukemia Michael Hallek, Center for Integrated Oncology (CIO) Cologne/Bonn, University Hospital Cologne, Cologne 10:00 10:30 Coffee Break 10:30 10:50 A blood gene expression-based test for early detection of colorectal cancer: final report of an international multi-center case-control study Gian Dorta, Lausanne University Hospital, Lausanne 11:00 11:20 Tumour-educated monocytes for diagnosis and disease follow-up of colorectal cancer Alexander Hamm, Heidelberg University Hospital, Heidelberg 11:30 11:45 Coffee Break

7 NOVEMBER 17 TH :45-13:00 Session III: Oncology Pipeline Chairs: Wolff Schmiegel / Georg Ralle 11:45 11:55 New medicines impacting lives of cancer patients Daniel Kalanovic, Pfizer Pharma Germany 12:00 12:10 Immuno-oncology by MSD: pembrolizumab and beyond Carine Keppens, MSD Sharp & Dohme GmbH, Haar 12:15 12:25 An insight into the Roche pipeline - an outlook into the future Christiane Langer, Roche Pharma AG, Grenzach-Wyhlen 12:30 12:40 Detection of neoplasia in the colorectum Impact of novel endoscopic techniques Alexander Dechêne, University Hospital Essen (on behalf of Olympus Deutschland GmbH), Hamburg 12:45 12:55 Screening for colorectal cancer strategy to improve adenoma detection rate Karl-Heinz Weiss, Heidelberg University Hospital, Heidelberg (on behalf of Norgine GmbH, Marburg) 13:00 14:00 Lunch

8 NOVEMBER 17 TH :00-17:00 Session IV: Innovative Therapeutic Approaches: Immunotherapy Chairs: Dirk Jäger / Ugur Sahin 14:00 14:20 Recent breakthroughs in immunotherapy of cancer Pedro Romero, Ludwig Center for Cancer Research, University of Lausanne, Lausanne 14:30 14:50 Immunotherapy for brain tumors Michael Platten, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg 15:00 15:20 Biomarker-supported development of an immune-effector-mobilizing antibody against a novel cancer cell surface target Özlem Türeci, Ganymed Pharmaceuticals AG, Mainz 15:30 16:00 Coffee Break 16:00 16:20 Engineering of chimeric antigen receptor (CAR)-modified T cells for immunotherapy of cancer Michael Hudecek, University Hospital Würzburg, Würzburg 16:30 16:50 The immune biology of DNA mismatch repair deficient cancer: basic concepts and clinical applications Magnus von Knebel Doeberitz, Heidelberg University Hospital, Heidelberg

9 NOVEMBER 17 TH :00-18:00 Panel Discussion II: Innovations in Oncology Moderation: Joachim Müller-Jung / Johannes Bruns Michael Hallek, Center for Integrated Oncology (CIO) Cologne/Bonn, University Hospital Cologne, Cologne Jan Helfrich, DAK-Gesundheit, Hamburg Ursula Marschall, BARMER GEK Krankenkasse, Berlin Hagen Pfundner, Roche Pharma AG, Grenzach-Wyhlen Wolff Schmiegel, Ruhr-University/German Cancer Society (DKG), Bochum 18:00 Get Together at DKFZ **WITH FRIENDLY SUPPORT OF (PROMOTION AND PRESENTATION): ( ) ( ) ( ) ( )

10 Hosted by: Location: German Cancer Research Center (DKFZ) Communication Center, Lecture Hall Im Neuenheimer Feld 280, Heidelberg Information and Registration: Viktoria Reinhardt Phone: +49 (0) Fax: +49 (0) Online Registration: Site Map: UniversitätsKlinikum Heidelberg Stand: Sept. 2015

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

MDC CareerDay April 16, 2015 PROGRAM

MDC CareerDay April 16, 2015 PROGRAM FOYER, MDC.C 8:30 9:00 REGISTRATION 9:00 9:15 OPENING AND WELCOME Prof. Dr. Gary Lewin Chairman of the Scientific Council, Max Delbrück Center for Molecular Medicine (MDC) 1 9:15 10:00 KEYNOTE TALK I:

More information

International Symposium on Immunotherapy and Immunodeficiency

International Symposium on Immunotherapy and Immunodeficiency International Symposium on Immunotherapy and Immunodeficiency November 19 th 20 th, 2009 Lecture Hall, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 280 69120 Heidelberg, Germany Alliance on

More information

Big Data in Medicine

Big Data in Medicine Symposium Big Data in Medicine Joint Symposium of the German National Academy of Sciences Leopoldina and the Hasso Plattner Institute for Software Systems Engineering July 1-2, 2015 Hasso Plattner Institute

More information

5 th Heidelberg Myeloma Workshop

5 th Heidelberg Myeloma Workshop Scientific program 5 th Heidelberg Myeloma Workshop Current status and developments in diagnosis and therapy of Multiple Myeloma Congress venue: Lecture hall, Hospital for Internal Medicine Friday, 24

More information

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Open Innovation@BayerHealthCare Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to

More information

Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by

Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM. midwinter2015.org. Sponsored by Midwinter Conference 2015 January 17-22 Seefeld, Tyrol CONFERENCE PROGRAM Sponsored by SATURDAY, 17 January 18.00-19.00 Keynote lecture Richard Flavell Sponsored by 19.00 Welcome Reception Hosted by SUNDAY,

More information

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) 2nd International Symposium on Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Wednesday Oct 7th, 2015 Congress Center (Hörsaal 1 3) Marien Hospital Herne Accreditation by the Medical Chamber

More information

Marketplace Germany Business Choice in Europe. Marketplace Germany Business Choice in Europe SPEAKERS. Registration 1:00pm 1:30pm

Marketplace Germany Business Choice in Europe. Marketplace Germany Business Choice in Europe SPEAKERS. Registration 1:00pm 1:30pm February 26th, 2015 February 26th, 2015 Kevin Glass Headmaster, Atlanta International School (AIS), Torsten Janssen Chartered Accountant, Partner, Ebner Stolz GmbH & Co. KG, Germany Registration 1:00pm

More information

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO)

Scientific Committee. Andrés Cervantes (ESMO, GEICO) Antonio González (ESMO, GEICO) Andrés Poveda (ESMO, GEICO) Jan B. Vermorken (ESMO, GEICO) Under the Auspices of Organized by 10th International Symposium Advanced Ovarian Cancer: Optimal Therapy. Update Valencia, Spain, 6th March 2015 Directors Andrés Poveda Fundación Instituto Valenciano de

More information

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens

30-31. Advancesincancer immunologyand immunotherapy. announcement. October2015. Royal Olympic Hotel Athens Advancesincancer immunologyand immunotherapy 30-31 October2015 Royal Olympic Hotel Athens announcement Organizer Hellenic Oncology Research Group (HORG) Symposium chairs N. Kentepozidis, A. Kotsakis, M.

More information

National Center for Tumor Diseases Heidelberg

National Center for Tumor Diseases Heidelberg National Center for Tumor Diseases Heidelberg National Center for Tumor Diseases Heidelberg Contents 4 An Ideal Environment for Clinical Medicine and Research A home for the NCT NCT Board of Directors

More information

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter)

SORRENTO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

A Letter from MabVax Therapeutics President and Chief Executive Officer

A Letter from MabVax Therapeutics President and Chief Executive Officer A Letter from MabVax Therapeutics President and Chief Executive Officer Dear Fellow Stockholder: You have invested in MabVax Therapeutics because you share our passion for finding new therapies for the

More information

T u m o r D o r m a n c y

T u m o r D o r m a n c y 1 st O N COLille Symposium on T u m o r D o r m a n c y June 26, 2014 Lille, France Invited Speakers Julio Aguirre-Ghiso, Tisch Cancer Institute, New-York, USA Dormancy - Micrometastasis Marieke Essers,

More information

Summer School 2011 Berlin SFB Transregio 19

Summer School 2011 Berlin SFB Transregio 19 Summer School 2011 Berlin SFB Transregio 19 27th October 29th October 2011 Molecular Mechanisms and Consequences of Inflammatory Cardiomyopathy: State of the Art and Future Challenges Welcome Address

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

The 100,000 genomes project

The 100,000 genomes project The 100,000 genomes project Tim Hubbard @timjph Genomics England King s College London, King s Health Partners Wellcome Trust Sanger Institute ClinGen / Decipher Washington DC, 26 th May 2015 The 100,000

More information

Best of San Antonio Breast Cancer Symposium

Best of San Antonio Breast Cancer Symposium Best of San Antonio Breast Cancer Symposium 11:45 am - 5:00 pm 5800 Rockside Woods Blvd. About the Course The San Antonio Breast Cancer Symposium is an international meeting of laboratory and clinical

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America

Genomic Medicine The Future of Cancer Care. Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Genomic Medicine The Future of Cancer Care Shayma Master Kazmi, M.D. Medical Oncology/Hematology Cancer Treatment Centers of America Personalized Medicine Personalized health care is a broad term for interventions

More information

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1

1 page Overview. CONCURRENT 1D, 1E, 1F Biology & Pathogenesis Multi-Modality Immunology 1 1 page Overview 21 Oct Tuesday 1500 on REGISTRATION 1800 Welcome Reception & Cocktails at the Cape Town International Conference Centre (CTICC) 22 Oct Wednesday 0730 REGISTRATION 0830 OPENING 0900 PLENARY

More information

STATE OF THE ART INVITATION SATURDAY, JANUARY 30 TH, 2016 COMORBIDITIES AND ENVIRONMENTAL FACTORS INFLUENCING MULTIPLE SCLEROSIS

STATE OF THE ART INVITATION SATURDAY, JANUARY 30 TH, 2016 COMORBIDITIES AND ENVIRONMENTAL FACTORS INFLUENCING MULTIPLE SCLEROSIS 18 TH STATE OF THE ART SYMPOSIUM of the Swiss Multiple Sclerosis Society www.multiplesklerose.ch INVITATION SATURDAY, JANUARY 30 TH, 2016 KKL Luzern, Culture and Convention Centre COMORBIDITIES AND ENVIRONMENTAL

More information

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010

CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 CNIO Frontiers Meetings Molecular Cancer Therapeutics Madrid, March 8 10, 2010 Organisers S. Gail Eckhardt, University of Colorado Denver, Aurora, USA Roy S. Herbst, The University of Texas MD Anderson

More information

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle

Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle Sommaire projets sélectionnés mesure 29: Soutien à la recherche translationnelle TITLE PROJET NOM HOPITAL Assessment of tumor angiogenesis using PET/CT with 18 F-Galacto- RGD. (PNC_29_001) Division of

More information

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY

MEDICAL BREAKTHROUGHS RESEARCH SUMMARY MEDICAL BREAKTHROUGHS RESEARCH SUMMARY TOPIC: Training the Body to Fight Melanoma REPORT: 3823 BACKGROUND: Melanoma is the most dangerous form of skin cancer that can be hard to treat and fatal if not

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

Promises and challenges of developing new drugs in oncology

Promises and challenges of developing new drugs in oncology 3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San

More information

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C

ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC. Thursday 16th April 2015 13:10 14:20 Room C ELCC 2015 Industry Satellite Symposium The Treatment Roadmap for Squamous NSCLC Thursday 16th April 2015 13:10 14:20 Room C 1 Contents Programme.... 2 Welcome message.... 3 Faculty biographies.... 4 Symposium

More information

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009

PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 PX Therapeutics : the partner for early stage biotherapeutics development Biotuesday, May 5 2009 Christelle Dagoneau, PhD Business Development Director Company Profile Protein expert incorporated in 2000

More information

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype?

Lauren Berger: Why is it so important for patients to get an accurate diagnosis of their blood cancer subtype? Hello, I m Lauren Berger and I m the Senior Director of Patient Services Programs at The Leukemia & Lymphoma Society. I m pleased to welcome Dr. Rebecca Elstrom. Dr. Elstrom is an Assistant Professor in

More information

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer

18.5 Percent Overall Response Rate Observed in Pembrolizumab-Treated Patients with this Aggressive Form of Breast Cancer News Release Media Contacts: Annick Robinson Investor Contacts: Joseph Romanelli (514) 837-2550 (908) 740-1986 Stephanie Lyttle NATIONAL Public Relations (514) 843-2365 Justin Holko (908) 740-1879 Merck

More information

Targeted Therapeutics Propelling Discovery through Genomic Data

Targeted Therapeutics Propelling Discovery through Genomic Data Two Innovative Events for Accelerating Science and Data Interpretations into Effective Treatments November 5-6, 2015 Hilton San Francisco Union Square Hotel San Francisco, CA Propelling Discovery through

More information

SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime

SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime SAP Healthcare Analytics Solutions Provide physicians and researchers access to patient data from various systems in realtime Stephan Schindewolf, SAP SE, July 13, 2015 Facts per Decision Need Decision

More information

Houston Cancer Institute

Houston Cancer Institute Houston Cancer Institute A personal path to healing Memorial-West Houston Katy Northwest Houston Southeast Houston Sugar Land Convenience for Patients State of the Art Therapies and Diagnosis Real Support

More information

How To Make Cancer A Clinical Sequencing

How To Make Cancer A Clinical Sequencing 10 this time, it s Personal In what is an exciting era in the evolution of oncology treatment, this special feature by Deborah J. Ausman explores how Next-Generation Sequencing and Convergent Informatics

More information

JUNE 2-3, 2014 CONNECT.

JUNE 2-3, 2014 CONNECT. JUNE 2-3, 2014 CONNECT. GROW. SUCCEED. THIRD INDUSTRIAL CELL CULTURE TECHNOLOGY CONFERENCE JUNE 2-3, 2014 Laupheim s historical castle, Schloss Großlaupheim, Germany Rentschler Biotechnologie GmbH is delighted

More information

TEACH Summer School Cascais, Portugal 3-7 July, 2016. Training and Education for Advanced Clinicians and HCPs in Personalised Medicine

TEACH Summer School Cascais, Portugal 3-7 July, 2016. Training and Education for Advanced Clinicians and HCPs in Personalised Medicine TEACH Summer School Cascais, Portugal 3-7 July, 2016 Training and Education for Advanced Clinicians and HCPs in Personalised Medicine TEACH Summer School Cascais, Portugal 3-7 July, 2016 Objectives There

More information

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending...

TABLE OF CONTENTS. Introduction...1. Chapter1 AdvancesinTreatment...2. Chapter2 MedicinesinDevelopment...11. Chapter3 ValueandSpending... CANCER TABLE OF CONTENTS Introduction...1 Chapter1 AdvancesinTreatment...2 Chapter2 MedicinesinDevelopment......11 Chapter3 ValueandSpending......15 Chapter4 Conclusion...22 INTRODUCTION Researchers and

More information

5th International Advanced ICAS Training Course on "Blood Stem Cell Transplantation: State of the Arts, Methods and Perspectives" 22-25 June 2009

5th International Advanced ICAS Training Course on Blood Stem Cell Transplantation: State of the Arts, Methods and Perspectives 22-25 June 2009 International Center for Advanced Studies in Health Sciences and Services (ICAS) of the Medical Faculty, University of Ulm Germany http://icas.uni-ulm.de 5th International Advanced ICAS Training Course

More information

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015

MOLOGEN AG. Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer. Berlin, 12 May 2015 Q1 Results 2015 Conference Call Dr. Matthias Schroff Chief Executive Officer Berlin, 12 May 2015 V1-6 Disclaimer Certain statements in this presentation contain formulations or terms referring to the future

More information

The University is comprised of seven colleges and offers 19. including more than 5000 graduate students.

The University is comprised of seven colleges and offers 19. including more than 5000 graduate students. UNC CHARLOTTE A doctoral, research-intensive university, UNC Charlotte is the largest institution of higher education in the Charlotte region. The University is comprised of seven colleges and offers 19

More information

Scientific Programme

Scientific Programme Scientific Programme Scientific Committee Hilary Calvert UCL Cancer Institute, London, UK Luca Gianni Ospedale San Raffaele IRCCS, Milan, Italy Ana Maria Gonzalez-Angulo Cristiana Sessa Istituto Oncologico

More information

EVT Execute & EVT Innovate Leading drug discovery

EVT Execute & EVT Innovate Leading drug discovery EVT Execute & EVT Innovate Leading drug discovery Evotec AG, Nine-month 2015 Interim Report, 10 November 2015 Forward-looking statements Information set forth in this presentation contains forward-looking

More information

Roche Position on Human Stem Cells

Roche Position on Human Stem Cells Roche Position on Human Stem Cells Background Stem cells and treating diseases. Stem cells and their applications offer an enormous potential for the treatment and even the cure of diseases, along with

More information

6HFRQG$QQRXQFHPHQW 6FLHQFHWR0DUNHW $'LVFXVVLRQDQG3DUWQHULQJ&RQIHUHQFH IRU([SHUWVIURP$FDGHPLD%LRWHFKQRORJ\ DQG3KDUPDFHXWLFDO,QGXVWU\

6HFRQG$QQRXQFHPHQW 6FLHQFHWR0DUNHW $'LVFXVVLRQDQG3DUWQHULQJ&RQIHUHQFH IRU([SHUWVIURP$FDGHPLD%LRWHFKQRORJ\ DQG3KDUPDFHXWLFDO,QGXVWU\ 6HFRQG$QQRXQFHPHQW 6FLHQFHWR0DUNHW $'LVFXVVLRQDQG3DUWQHULQJ&RQIHUHQFH IRU([SHUWVIURP$FDGHPLD%LRWHFKQRORJ\ DQG3KDUPDFHXWLFDO,QGXVWU\ 2FWREHU± &RQYHQWLRQ&HQWHU+DQQRYHU*HUPDQ\ 2UJDQLVHGE\ WKH(XURSHDQ$VVRFLDWLRQRI3KDUPD%LRWHFKQRORJ\($3%

More information

QUANTITATIVE APPROACHES IN CELL BIOLOGY BIOPHYSICS, BIOENGINEERING & SYSTEMS BIOLOGY

QUANTITATIVE APPROACHES IN CELL BIOLOGY BIOPHYSICS, BIOENGINEERING & SYSTEMS BIOLOGY QUANTITATIVE APPROACHES IN CELL BIOLOGY BIOPHYSICS, BIOENGINEERING & SYSTEMS BIOLOGY SignGene Symposium 2014 August 31 - September 2, 2014 Max Delbrück Center for Molecular Medicine Berlin, Germany www.mdc-berlin.de/signgenesymposium2014

More information

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy

Programme. Michele Grieco Dipartimento di Scienze Ambientali Seconda Università degli Studi di Napoli Naples, Italy Programme Invited Speakers: Reuven Agami (The Netherlands), Manuela Baccarini (Austria), Allan Balmain (USA), Daniel Birnbaum (France), Anne-Lise Børresen-Dale (Norway), Carlos Caldas (UK), Silvana Canevari

More information

Avastin in Metastatic Breast Cancer

Avastin in Metastatic Breast Cancer Non-interventional study Avastin in Metastatic Breast Cancer ML 21165 / 2007 Clinical Study Report Synopsis ROCHE ML21165 / WiSP Project RH09 / V. 1.0 / 24.06.2013 ROCHE ML21165-2 - Name of Sponsor Roche

More information

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium

9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium 9 th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) 9th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPD/C) Szeged,

More information

Future Oncology: Technology, Products, Market and Service Opportunities

Future Oncology: Technology, Products, Market and Service Opportunities Brochure More information from http://www.researchandmarkets.com/reports/296370/ Future Oncology: Technology, Products, Market and Service Opportunities Description: Future Oncology is an analytical newsletter

More information

POST-CONGRESS SATELLITE MEETINGS May 24 th, 2013. Cancer biomarkers 2013

POST-CONGRESS SATELLITE MEETINGS May 24 th, 2013. Cancer biomarkers 2013 20 th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine 45 th Congress of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) POST-CONGRESS SATELLITE

More information

Resumen Curricular de los Profesores. Jesse Boehm

Resumen Curricular de los Profesores. Jesse Boehm Resumen Curricular de los Profesores Jesse Boehm Jesse Boehm is the assistant director of the Cancer Program at the Broad Institute. In this role, he works closely with Cancer Program director Todd Golub

More information

HARVARD MEDICAL SCHOOL

HARVARD MEDICAL SCHOOL HARVARD MEDICAL SCHOOL CANCER BIOLOGY & THERAPEUTICS PROGRAM CBT A joint initiative of the Harvard Medical School Office of Global Education and the Qatar Biomedical Research Institute (QBRI) 2015-2016

More information

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05

BOLT Hem/Onc Thought Leader Panel #38 Cancer Immunotherapy 2014-05 Syndicated Thought Leader Insight Healthcare & Pharmaceutical Research Cancer Immunotherapy Melanoma, Non- Small Cell Lung Cancer, Renal Cell Carcinoma Thought Leader Panel #38 2014-05 Therapeutic Area:

More information

Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision

Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Vision for the Cohort and the Precision Medicine Initiative Francis S. Collins, M.D., Ph.D. Director, National Institutes of Health Precision Medicine Initiative: Building a Large U.S. Research Cohort

More information

ITT Advanced Medical Technologies - A Programmer's Overview

ITT Advanced Medical Technologies - A Programmer's Overview ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) ITT Advanced Medical Technologies (Ileri Tip Teknolojileri) is a biotechnology company (SME) established in Turkey. Its activity area is research,

More information

ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN

ORGANIZERS Fundación para la Investigación Médica Aplicada FIMA Clínica Universidad de Navarra CUN D International Symposium: Immunostimulatory monoclonal antibodies and immunomodulation: harvesting the crop Fundación Ramón Areces GENERAL INFORMATION DATES OCTOBER 18th 20th VENUE University of Navarra.

More information

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014

Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology. November 17, 2014 Pfizer Forms Global Alliance with Merck KGaA, Darmstadt, Germany to Accelerate Presence in Immuno-Oncology November 17, 2014 Forward-looking statements Our discussions during this conference call will

More information

EBiSC the first European bank for induced pluripotent stem cells

EBiSC the first European bank for induced pluripotent stem cells Press Release EBiSC the first European bank for induced pluripotent stem cells Pharmaceutical companies who are members of the European Federation of Pharmaceutical Industries and Associations (EFPIA)

More information

Resolving Cancer Heterogeneity:

Resolving Cancer Heterogeneity: INTERNATIONAL SYMPOSIUM ON: Resolving Cancer Heterogeneity: The way to personalised medicine Palazzo della Gran Guardia Verona (Italy), June 30 th July 2 nd, 2016 PROGRAM Organized by: ARC-Net Centre for

More information

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies

Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies PRESS RELEASE Servier Exercises Exclusive Worldwide Licensing Option with Cellectis for UCART19, an Allogeneic CAR-T Cell Therapy for Hematological Malignancies Servier Also Enters Into Exclusive Global

More information

International Symposium on Malignant Pleural Mesothelioma

International Symposium on Malignant Pleural Mesothelioma International Symposium on Malignant Pleural Mesothelioma LONDON 2015 Friday 6th & Saturday 7th November 2015 Jumeirah Carlton Tower Hotel Cadogan Place Knightsbridge London SW1X 9PY United Kingdom Dear

More information

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient

Understanding series. new. directions. 1-800-298-2436 LungCancerAlliance.org. A guide for the patient Understanding series LUNG CANCER: new treatment directions 1-800-298-2436 LungCancerAlliance.org A guide for the patient TABLE OF CONTENTS What s New in lung cancer? Advancements...4 Changes in genes that

More information

Report series: General cancer information

Report series: General cancer information Fighting cancer with information Report series: General cancer information Eastern Cancer Registration and Information Centre ECRIC report series: General cancer information Cancer is a general term for

More information

Promises and challenges of developing new drugs in oncology

Promises and challenges of developing new drugs in oncology 3 rd International Michelangelo Conference Promises and challenges of developing new drugs in oncology Chairman: Luca Gianni, Milan I July 2-3, 2015 Venue: Museo della Scienza e della Tecnologia Via San

More information

8 th International VPM Days Hannover 2015

8 th International VPM Days Hannover 2015 Program 2015 Thursday September 17 th, 2015 12.00 13.00 Registration and Snacks 13.00 13.30 Welcome & opening remarks Dr. Bernd Eisele (VPM) & Marina Lerch (hannoverimpuls) Key Note Lecture: 13.30 14.00

More information

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing

Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing Individualizing Your Lung Cancer Care: Informing Decisions Through Biomarker Testing These Are Hopeful Times for Lung Cancer Survivors When people first learn they have cancer, they are often afraid. But

More information

A Career in Pediatric Hematology-Oncology? Think About It...

A Career in Pediatric Hematology-Oncology? Think About It... A Career in Pediatric Hematology-Oncology? Think About It... What does a pediatric hematologist-oncologist do? What kind of training is necessary? Is there a future need for specialists in this area? T

More information

American Cancer Society Extramural Grants

American Cancer Society Extramural Grants Page: 1 Doctoral Training Grant in Oncology Social Work Renewal (DSWR) DSWR-14-087-03 Blinka, Marcela, MSW MENTOR: BrintzenhofeSzoc, Karlynn, MSW, DSW, PhD The Catholic University of America National Catholic

More information

Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008

Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers. Mont Ste. Odile, Alsace, France 11-14 September 2008 33 rd European Symposium on Hormones and Cell Regulation Understanding the Molecular and Cellular Biology of Endocrine-Related Cancers Mont Ste. Odile, Alsace, France 11-14 September 2008 Invited Speakers:

More information

CANCER SUMMER SCHOOL 2014 PROGRAM

CANCER SUMMER SCHOOL 2014 PROGRAM CANCER SUMMER SCHOOL 2014 PROGRAM Monday 30 th June 0 Participant Arrival & Coffee Break ED 3 room Presentation of the program Presentation of the participants and of their research interests/experiences

More information

Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1

Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 9/8/2015 Identification of CD4+ T cell epitopes specific for the breast cancer associated antigen NY-BR-1 Stefan Eichmüller, PhD GMP & T Cell Therapy Unit, German Cancer Research Center, Heidelberg, Germany

More information

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for

Achievements Report CURING CANCER. Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for Achievements Report August 2015 CURING CANCER Of all the questions addressed to CPRIT, the toughest is: When are you going to find a cure for cancer? Since cancer is complex and comes in many forms, its

More information

Monoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C

Monoclonal Antibody Therapy: Innovations in Cancer Treatment. James Choi ENGL 202C Monoclonal Antibody Therapy: Innovations in Cancer Treatment James Choi ENGL 202C Treating Cancer with Monoclonal Antibody Therapy Researchers and scientists have been working for decades to find a cure

More information

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute

Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia EXECUTIVE SUMMARY. New England Healthcare Institute Targeting Cancer: Innovation in the Treatment of Chronic Myelogenous Leukemia New England Healthcare Institute NEHI Innovation Series March 2004 Executive Summary From drugs and medical devices, to information

More information

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview

Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Brochure More information from http://www.researchandmarkets.com/reports/3066973/ Cancer Immunotherapy: immune checkpoint inhibitors, cancer vaccines, and adoptive T-cell therapies - Overview Description:

More information

Global Monoclonal Antibodies Pipeline Insight 2015

Global Monoclonal Antibodies Pipeline Insight 2015 Brochure More information from http://www.researchandmarkets.com/reports/3113388/ Global Monoclonal Antibodies Pipeline Insight 2015 Description: Ever since the Nobel Prize was bestowed on the person who

More information

Equity markets Major advances in cancer therapeutics 18 August 2015

Equity markets Major advances in cancer therapeutics 18 August 2015 Major advances in cancer therapeutics 18 August 2015 CIO WM Research Jerome Brimeyer, Equity Sector Strategist, jerome.brimeyer@ubs.com Our cancer therapeutics investment theme recommends companies that

More information

1. WHY ARE ELECTRONIC MEDICAL RECORDS IMPORTANT FOR PERSONALIZED MEDICINE?

1. WHY ARE ELECTRONIC MEDICAL RECORDS IMPORTANT FOR PERSONALIZED MEDICINE? THE ELECTRONIC MEDICAL RECORD: A CRITICAL ISSUE IN PERSONALIZED MEDICINE 1. WHY ARE ELECTRONIC MEDICAL RECORDS IMPORTANT FOR PERSONALIZED MEDICINE? As initially configured, electronic medical records (EMRs)

More information

GOOD CLINICAL PRACTICE PROGRAM. Workshop 2006 DC THERA. November 27th 28th 2006, Dorint Hotel Erlangen, Germany

GOOD CLINICAL PRACTICE PROGRAM. Workshop 2006 DC THERA. November 27th 28th 2006, Dorint Hotel Erlangen, Germany DC THERA Dendritic Cells & New Immunotherapies EU Sixth Framework Programme Life Science, Genomics and Biotechnology for Health DC-THERA Dendritic Cells & New Immunotherapies Network of Excellence, Project

More information

How To Improve Cancer Care In Germany

How To Improve Cancer Care In Germany Deutsches Krebskonsortium (DKTK) und Nationales Centrum für Tumorerkrankungen Heidelberg (NCT) Ist Deutschland jetzt konkurrenzfähig? DGIM Opinion Leader Meeting, Eltville-Erbach, 17. -18. Januar 2014

More information

BIOSCIENCES COURSE TITLE AWARD

BIOSCIENCES COURSE TITLE AWARD COURSE TITLE AWARD BIOSCIENCES As a Biosciences undergraduate student at the University of Westminster, you will benefit from some of the best teaching and facilities available. Our courses combine lecture,

More information

Guideline Development The American Society of Clinical Oncology

Guideline Development The American Society of Clinical Oncology Assessing Genomic Sequencing Information for Health Care Decision Making Decision Making Once Evidence is Assessed/Graded Evaluated Guideline Development The American Society of Clinical Oncology Gary

More information

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD

CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD CLINICAL TRIALS SHOULD YOU PARTICIPATE? by Gwen L. Nichols, MD Gwen L. Nichols, M.D., is currently the Oncology Site Head of the Roche Translational Clinical Research Center at Hoffman- LaRoche. In this

More information

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing

Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Fit for Health 2.0 - International Strategy Development Training Innovative Business Solutions and Smart Financing Thursday 08 October 2015 8-9 October 2015, Copenhagen (Denmark) Medicon Valley Alliance,

More information

StemCellMathLab 2016. Systems Medicine of Leukemia

StemCellMathLab 2016. Systems Medicine of Leukemia StemCellMathLab 2016 8 th International Workshop on Models and Concepts of Stem Cell Organization Systems Medicine of Leukemia June 16 th -18 th, 2016 - Hamburg, Germany Scientific Programme Thursday,

More information

Ask Us About Clinical Trials

Ask Us About Clinical Trials Ask Us About Clinical Trials Clinical Trials and You. Our specialists and researchers are at the forefront of their fields and are leading the way in developing new therapies and procedures for diagnosing

More information

Centre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies

Centre for Biomarker Research in Medicine. COMET Competence Centre for Excellent Technologies Centre for Biomarker Research in Medicine COMET Competence Centre for Excellent Technologies Why Biomarker Research? early diagnosis, often before manifestation identification of at-risk patients for new

More information

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE

Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE Digital Health: Catapulting Personalised Medicine Forward STRATIFIED MEDICINE CRUK Stratified Medicine Initiative Somatic mutation testing for prediction of treatment response in patients with solid tumours:

More information

Breakthrough Treatment Options for Breast Cancer

Breakthrough Treatment Options for Breast Cancer Breakthrough Treatment Options for Breast Cancer Guest Expert: Lyndsay, MD Associate Professor of Medical Oncology, Yale Cancer Center www.wnpr.org www.yalecancercenter.org Welcome to Yale Cancer Center

More information

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT

GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT GRANT APPLICATION FORM: ORGANISING AN ESO EDUCATIONAL EVENT 1) TOPIC OF THE EVENT MALIGNANT PLEURAL DISEASE 2) SUGGESTED TITLE : Approach to Pleural Cancer: State-of-the-Art 3) TYPE OF EVENT Course Native

More information

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma

News Release. Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma Your Contacts News Release Merck KGaA, Darmstadt, Germany Media: Markus Talanow +49 6151 72 7144 Investor Relations +49 6151 72 3321 Pfizer Inc., New York, USA Media: Sally Beatty +1 212 733 6566 Investor

More information

Worldwide Collaborations in Molecular Profiling

Worldwide Collaborations in Molecular Profiling Worldwide Collaborations in Molecular Profiling Lillian L. Siu, MD Director, Phase I Program and Cancer Genomics Program Princess Margaret Cancer Centre Lillian Siu, MD Contracted Research: Novartis, Pfizer,

More information

Therapeutic Systems Immunology

Therapeutic Systems Immunology Therapeutic Systems Immunology Coordination: Robert Preissner, Charité, Berlin 13 Partners from Berlin (7) Göttingen (1) Heidelberg (1) Rostock (2) Tübingen (1) Overview Intro / Mission Partners Systems

More information

Clinical Cancer Genomes. on behalf of the GA4GH Clinical Working Group

Clinical Cancer Genomes. on behalf of the GA4GH Clinical Working Group Clinical Cancer Genomes Mark Lawler (Queen s University Belfast and GA4GH Clinical Working Group) on behalf of the GA4GH Clinical Working Group Disclosure Statement Disclosure Statement I have nothing

More information

Cancer Services for Adults and Children

Cancer Services for Adults and Children UCSF HEALTH Cancer Services for Adults and Children Our world-class clinical and research programs are engaged in the urgent effort to cure cancers and, where cures currently elude us, transform cancer

More information

High Performance Computing Initiatives

High Performance Computing Initiatives High Performance Computing Initiatives Eric Stahlberg September 1, 2015 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute Frederick National Laboratory is

More information

Multi-Agent Systems. Expert Forum Agents within the context of Industry 4.0. Industry 4.0 Machine Learning. Energy and Smart Grids.

Multi-Agent Systems. Expert Forum Agents within the context of Industry 4.0. Industry 4.0 Machine Learning. Energy and Smart Grids. Multi-Agent Systems Event Expert Forum Agents within the context of Industry 4.0 Industry 4.0 Machine Learning Material Handling Energy and Smart Grids Energy Management Production Control Operations Scheduling

More information